Clinical Trials Logo

Filter by:
NCT ID: NCT04894942 Not yet recruiting - Clinical trials for Calcaneonavicular Coalition

Evaluation of Clinical Features and Surgical Outcomes of the Too Long Anterior Process in Children

Start date: July 2021
Phase:
Study type: Observational

Calcaneonavicular coalition represents approximately 1% of the population between 8 and 12 years. They are manifested by repeated ankle sprains or by pain. - The diagnosis is radiological on an X-ray of the foot in oblique-3/4 incidence as well as magnetic resonance imaging. Treatment is second-line surgery after failure of orthopedic treatment. This surgery is either by direct approach or by arthroscopy, by performing a bone resection to recreate sufficient space in the joint in question. The patients in this study will only be operated on openly.

NCT ID: NCT04894370 Recruiting - Clinical trials for Metastatic Squamous Cell Carcinoma

Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma

SPARTANA
Start date: June 9, 2022
Phase: Phase 2
Study type: Interventional

This study evaluates the feasibility of the combination of radiotherapy, chemotherapies (docetaxel, cisplatin and 5-fluorouracil) and spartalizumab (anti-PD-1 therapy) in patients with metastatic squamous cell anal carcinoma

NCT ID: NCT04894253 Recruiting - Systemic Lupus Clinical Trials

Immune Response to SARS-CoV-2 Vaccination in Systemic Lupus

LUPCELLVAX
Start date: June 7, 2021
Phase:
Study type: Observational [Patient Registry]

The main objective is to study the impact of vaccination against Covid-19 on the specific humoral and cellular immune response (against SARS-CoV-2) and non-specific (evolution of the pathological immune system of the disease), in a lupus population. The secondary objective is to study the impact of lupus disease activity on the humoral and cellular response of patients following vaccination against SARS-CoV-2. The hypothesis is that disease activity and / or certain treatments used in lupus may interfere with the humoral and cellular immune response induced by vaccination against SARS-CoV-2.

NCT ID: NCT04894175 Completed - Clinical trials for Obstructive Sleep Apnea

Association Between Treatment Adherence and Treatment Adherence in Sleep Apnea (SEMSAS)

SEMSAS
Start date: May 25, 2021
Phase:
Study type: Observational

The objective of the study is to define an optimal threshold of the SEMSA-15 scale for obstructive sleep apnea (OSA) perception in patients with OSA to predict 3-month and 1-year continuous positive airway pressure adherence.

NCT ID: NCT04894123 Terminated - Clinical trials for Colorectal Adenocarcinoma

Cardiovascular Events From Trifluridine/Tipiracil +/- Oxaliplatin in Colorectal/Oesogastric Adenocarcinoma Patients

Start date: February 7, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the incidence of cardiovascular events in patients with esophageal/stomach or colorectal cancer treated by trifluridine/tipiracil +/- oxaliplatin after an episode of cardiac angina-related thoracic pain due to fluoropyrimidines in the adjuvant or metastatic setting .

NCT ID: NCT04893954 Recruiting - Clinical trials for Low Back Pain in Obese Patients After Important Weight Loss

Prospective Study on the Consequences of Weight Loss After Bariatric Surgery on Obese Patients' Spine.

SPINOB
Start date: June 3, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to determine how an important weight loss after bariatric surgery affects obese patients ' spine, and the effects it has on low back pain, sagittal alignment and lipomatosis .

NCT ID: NCT04893564 Withdrawn - Clinical trials for Waldenstrom Macroglobulinemia

Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia

SLP-rares
Start date: May 14, 2021
Phase: N/A
Study type: Interventional

Waldenström Macroglobulinemia (WM) is defined by a bone marrow lymphoplasmacytic infiltration and the presence of a monoclonal immunoglobulin M (IgM) in blood. This chronic lymphoproliferative disorder requires treatment only in case of symptoms, according to accurate criteria described during the second Workshop on WM i.e. in case of cytopenia, bulky organomegaly, immunological or physicochemical consequences of the presence of IgM in circulating blood. A MYD88 mutation, typically a MYD88(L265P), is found in 90% of WM patients. Other gene abnormalities have been observed, the most frequent is a mutation in the CXCR4 gene. Overall, gene mutations in WM involve only a limited number of signalling pathways, yielding the activation of NFkB, namely : the TLR and MYD88 pathway (with an activation of NFkB and BTK in case of MYD88(L265P) mutation), the BCR pathway (involving btk and associated with activations of both NFkB, and erk akt pathway) and the CXCR4 pathway (CXCR4 is a receptor of CXCL12, it is also associated with activations of ERK/MAPK and PI3K). Abnormalities of some of genes, such as TP53, of the expression of the protein CXCL13 and genes involved in the interleukin 6 secretion have been associated with some clinical characteristics. The purpose of this project is to define the prognostic role of the detection of circulating tumoral DNA (ctDNA) at the end of treatment for the progression/relapse risk within the first 3 years after the first 6 months of treatment.

NCT ID: NCT04893330 Completed - Clinical trials for Milk Hypersensitivity

Interest of Peticate Syneo Infant Formula in Children Allergic to Cow's Milk Protein: Real Life Study

PEPSY
Start date: June 23, 2021
Phase:
Study type: Observational

Nutricia wants to launch a real-life study, to see how the presence of prebiotics and probiotics in the boosted protein hydrolyzate can improve symptoms in the first weeks of use, and supplement the efficacy and safety data of the drug. formula, collected during clinical trials, with real life use. The target population will be children with a definite or suspected diagnosis of APLV, who have never taken a hypoallergenic formula, for whom the doctor decides to prescribe the Pepsicate Syneo formula, regardless of the clinical manifestation of the allergy. These children will be included before the age of 8 months and will be seen again 4 weeks after the prescription. The data from this real-life study will also better characterize the profile of infants taking Pepsicate Syneo. Finally, the perception of the formula by the parents will be collected.

NCT ID: NCT04893317 Active, not recruiting - Clinical trials for Monomorphic Ventricular Tachycardia

Cryoablation for Monomorphic Ventricular Tachycardia (CryoCure-VT)

CryoCure-VT
Start date: May 26, 2021
Phase: N/A
Study type: Interventional

A prospective, single-arm, multi-center, pre-market, clinical study designed to provide safety and performance data regarding the use of the Adagio Medical VT Cryoablation System in the treatment of ventricular tachycardia.

NCT ID: NCT04893291 Recruiting - Clinical trials for Coronary Artery Disease

Sirolimus-coated Balloon Versus Drug-eluting Stent in Native Coronary Vessels

TRANSFORM II
Start date: November 16, 2021
Phase: N/A
Study type: Interventional

International, multicentric, prospective, investigator-driven, open-label, randomized (1:1) clinical trial to observe and evaluate the efficacy, of Magic Touch Sirolimus Coated Balloon (SCB) compared to one of the gold standard treatment for native vessel disease (everolimus-eluting stent, EES).